Biopharma M&A Volume, Value Bounced Back Significantly In Q4

Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.

M&A activity picked up noticeably in Q4 after a downturn in Q3

Merger and acquisition activity in Q4 2023 flipped the script after a sluggish third quarter, with 10 transactions valued at $1bn or more and two valued above $10bn, according to data recorded by Evaluate. A total of 39 biopharma M&A deals during the quarter with an aggregate value of nearly $59bn accounted for a more than 60% increase in deal volume, while aggregate value rose more than four-fold from quarter to quarter.

The increase in deal volume from 24 to 39 put the industry’s M&A pace back on track as the sector...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.